NASDAQ$KALV

KalVista Pharmaceuticals Inc · Q1 2016 earnings

Q1 2016 earnings · · Investor relations

Headline financials

Total Revenue

$7K

No prior period
EPS (adj)

-$5.18

No prior period
Net Income

-$9.01M

No prior period
Operating Income

-$5.67M

No prior period
Gross Profit

$7K

No prior period
R&D Expense

$4.5M

No prior period

Revenue & EPS history

KalVista · Revenue · Quarterly

$7K

Q1 2016
Beat estimate in 2 of 8 quarters(25%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

-0.3%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.7%

Avg return

30 days after

49%

21 / 43 earnings

Positive

+20.3%

Q4 2018

Best reaction

-26.3%

Q3 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+1.1%+26.3%+56.4%
Q1 2026-3.8%-12.3%-25.3%
Q4 2025-3.1%-5.1%-22.4%
Q3 2025+2.0%-2.6%+5.1%
Q2 2025-4.2%-0.2%-4.5%
Q1 2025-4.5%-13.2%-12.1%
Q4 2024+3.7%+21.3%+2.6%
Q3 2024-13.0%-16.9%-16.9%
Q2 2024-9.0%+8.8%+26.8%
Q1 2024-4.0%-4.2%-12.2%
Q4 2023+17.0%+7.6%+23.5%
Q3 2023-10.4%-1.3%+2.7%
Q2 2023+9.8%+7.3%+27.8%
Q1 2023+1.4%-2.5%-68.4%
Q4 2022+10.6%+18.0%+37.5%
Q3 2022-9.3%-14.6%-16.4%
Q2 2022-0.4%-2.9%-4.2%
Q1 2022-0.6%-6.0%-14.4%
Q4 2021-3.0%-2.9%-14.0%
Q3 2021+3.4%+8.9%-16.8%
Q2 2021+5.2%+5.1%-7.0%
Q1 2021+2.0%+1.3%+9.8%
Q4 2020+7.2%+4.2%-18.8%
Q3 2020-26.3%-41.2%-20.9%
Q2 2020-1.8%-5.7%+18.9%
Q1 2020+8.7%+1.0%-29.4%
Q4 2019-0.5%+1.4%-6.7%
Q3 2019+10.4%+7.6%-0.2%
Q2 2019-14.0%-21.2%-15.5%
Q1 2019+9.6%+4.6%+20.6%
Q4 2018+20.3%+29.8%+94.0%
Q3 2018+4.7%+11.7%+0.8%
Q2 2018-4.8%-12.3%+0.2%
Q1 2018-21.5%-23.6%+9.8%
Q4 2017-0.8%-2.7%-11.6%
Q3 2017+1.9%-1.0%-12.2%
Q2 2017-1.9%-2.9%-1.6%
Q1 2017+0.4%+13.1%-13.3%
Q4 2016-3.2%
Q3 2016+7.1%
Q2 2016-3.2%
Q1 2016+1.3%
Q4 2015+2.4%
Q3 2015
Q2 2014
Q1 2014
Q4 2014
Q3 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro